Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas

To cite this version:
Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas

Matthieu Peyre\textsuperscript{1,2,3}, M.D., Ph.D., Marc Zanello\textsuperscript{1}, M.D., Karima Mokhtari\textsuperscript{2,4}, M.D., Anne-Laure Boch\textsuperscript{1}, M.D., Ph.D., Laurent Capelle\textsuperscript{1}, M.D., Alexandre Carpentier\textsuperscript{1,3}, M.D., Ph.D., Stephane Clemenceau\textsuperscript{1}, M.D., Carine Karachi\textsuperscript{1,3}, M.D., Ph.D., Soledad Navarro\textsuperscript{1}, M.D., Aurelien Nouet\textsuperscript{1}, M.D., Vincent Reina\textsuperscript{1,3}, M.D., Ph.D., Charles-Ambroise Valery\textsuperscript{1}, M.D., Marc Sanson\textsuperscript{2,3,5}, M.D., Ph.D., Philippe Cornu\textsuperscript{1,3}, M.D., Ph.D., Michel Kalamardes\textsuperscript{1,2,3}, M.D., Ph.D.

1 – AP-HP, Hôpital Pitié Salpêtrière, Department of Neurosurgery, Paris
2 – INSERM U1127 CNRS UMR 7225, Institut du Cerveau et de la Moelle Epinière, Paris
3 – Université Paris 6 - Pierre et Marie Curie, Paris
4 – AP-HP, Hôpital de La Pitié Salpêtrière, Department of Neuropathology, Paris
5 – AP-HP, Hôpital de La Pitié Salpêtrière, Department of Neuro-Oncology, Paris

Running title: Natural history of treatment-refractory meningiomas

Corresponding author: Michel Kalamardes
Adress: Service de Neurochirurgie, APHP, Hôpital Pitié Salpêtrière
47-83 bvd de l’Hôpital, 75013 Paris
Phone: 01 42 16 31 12
Fax: 01 42 16 34 16
Mail: michel.kalamardes@psl.aphp.fr

Word Count: 2938 words.
Abstract

Background: Patients with surgery- and radiation-refractory meningiomas have a poor outcome. Due to our lack of knowledge concerning multi-recurrent meningioma natural history, their clinical course is poorly defined. This retrospective study aims at defining patterns of relapse in order to help in the definition of response criteria in future clinical trials.

Methods: We performed a retrospective review of surgery- and radiotherapy-refractory meningioma cases with interpretable radiological follow-up treated in our department. Tumor volumes were measured on 3D T1 Gadolinium volumetric sequences using a semi-automated algorithm for tumor segmentation.

Results: Twenty nine patients with multi-treated meningioma (11 WHO Grade II, 5 de novo WHO Grade III and 13 transformed WHO Grade III), were evaluated. Median PFS was 16 months for patients with Grade II meningiomas. In patients with Grade III meningiomas, the de novo subgroup had a median PFS of 4 months compared with 7 months in patients with malignant transformation. Volumetric analysis of tumor growth concerned 95 tumor nodules in 50 relapses. The mean growth rate of tumor nodules was 45.8 cm³/year (95% CI: 16-75 cm³/year). Three patterns of tumor growth were described: « classical » for 9 (31%) patients, « local multi-nodular » for 6 (21%) patients and « multi-nodular metastatic » for the last 14 (48%) patients. Considering all tumor nodules, median time to tumor progression (TTP) was 3.7 months.

Conclusion: Progressing tumors represent the most frequent histological subgroup of surgery and radiation-refractory meningiomas while tumors with multi-nodular metastatic dissemination are the prominent radiological pattern of progression.

Keywords: Anaplastic Meningioma, Atypical meningioma, Recurrence, Natural history, Tumor progression
Introduction

Meningiomas are the most frequent central nervous system tumors in the adult population[1]. Most meningiomas are benign (WHO grade I) but there is a significant proportion of tumors classified as WHO grade II (atypical meningioma) or WHO grade III (anaplastic/malignant meningioma), and these exhibit more aggressive clinical behavior [2] and have a higher risk of recurrence [3,4] with increased mortality [5]. For several decades, the mainstay of treatment has been surgical resection for all meningioma grades, and post-operative radiotherapy in grade III tumors. But for a fraction of Grade II and most Grade III meningiomas, the current therapeutic strategies fail to achieve tumor control and are followed by significant morbidity and mortality. The lack of effective chemotherapies results in part from our limited understanding of atypical/malignant meningioma biology despite numerous molecular studies [6]. But the assessment of the efficacy of potential innovative treatments is also limited by our incomplete knowledge of multi-recurrent meningioma natural history especially concerning tumors with malignant transformation [11,12]. A recent meta-analysis underlined the absence of response criteria or well-documented benchmarks regarding overall survival (OS), progression-free survival (PFS), or 6-month PFS (PFS-6) for recurrent meningioma [13].

Here we perform a retrospective review of all surgery- and radiotherapy-refractory meningioma cases followed in our department focusing on the patterns and kinetics of tumor recurrence. We clearly identified and characterized three distinct patterns of tumor recurrence, highlighting the frequency of multi-nodular relapses and the variability of growth rates among concomitant nodules in the same patient.

Material and methods
Patient population. The aim of the study was to describe a specific patient population diagnosed with histologically-aggressive meningiomas eligible for a potential clinical trial for recurrent treatment-refractory tumors. Patients were selected from the database of the Department of Neuropathology from 1998 to 2013. Patients with Grade I meningiomas and/or long-term relapses (more than 10 years after first surgery) as well as patients with staged resections were excluded from the study. There was a total of 491 WHO Grade II meningiomas and 64 Grade III meningiomas operated upon during this period. In order to determine tumor kinetics, we selected patients with interpretable radiological follow-up, presenting at least one relapse with two distinct modalities of treatment and with a MRI at diagnosis and at surgery. The local institutional review board approved this retrospective chart review. All patients or their parents provided informed consent.

Imaging analysis. All tumors volumes were measured on 3D T1 Gadolinium volumetric sequences using OsiriX Software® and a semi-automated algorithm for tumor segmentation (SegmentiX®) by a single investigator (M.P). This algorithm was already validated for segmentation of other intracranial lesions, including brain arteriovenous malformations [14]. To validate this algorithm in meningioma measurements, we performed a manual segmentation in 10 tumors at diagnosis and compared the results with the volume determined by semi-automated segmentation leading to a mean difference of 4.2% (median: 3.1% - range: 1 - 9.3%). When meningiomas recurred not as a single tumor mass, but as a series of spatially distinct tumor nodules, all tumor nodules were measured separately. Only tumors greater than 1 cm in diameter were considered in the analysis. There was a total of 271 MRI scans analyzed with mean number of 9.3 MRI scans per patient (range: 3 - 24 MRI scans). A linear fit model was used to estimate meningioma growth. To estimate the slope of the growth curve
over time for each tumor nodule and each relapse, we performed linear regressions of the tumor volume over time, using the volumes at the time of relapse (initial volume) and at surgery (final volume). Tumor growth rate was calculated using the following formula: (final volume - initial volume)/follow-up interval. Time to tumor progression was defined as the time necessary to achieve a 20% increase in tumor volume starting from baseline. This criteria is based on studies performed in Neurofibromatosis type 2 patients who harbor meningiomas[15]. This choice is based on previous definitions of tumor response and progression in early phase II trials in Neurofibromatosis type I. This also corresponds roughly to a 2 mm change in diameter of a 22 mm diameter, which would be the typical threshold for reliable clinical measurement of a minimal change in a discrete tumor such as meningioma.

Anatomopathology. All cases were retrospectively reviewed by one pathologist (K.M) to determine tumor grade according to 2007 WHO criteria.

Results

Clinical characteristics of the cohort. Twenty nine patients, 14 females (48%) and 15 males (52%), with multi-recurrent meningioma were included in the study. The mean number of relapses per patient was 2.9 (range, 1-6). All patients underwent surgery with a mean number of interventions of 3.4 (range, 1-7) and a total of 91 surgical procedures. The extent of resection was defined as Simpson 1 in 10 cases (11%), Simpson 2 in 12 cases (13%), Simpson 3 in 8 cases (9%) and Simpson 4 in 51 cases (56%). Pathological analysis found 11 Grade II meningiomas, 13 transformed Grade III meningiomas (WHO Grade I or II with subsequent malignant transformation) and 5 de novo Grade III meningiomas. Fourteen patients received postoperative conformational radiotherapy: all 5 patients with de novo Grade III tumors, 7 patients with transformed Grade III tumors (67% of all Grade III tumors) and 2 patients with
Grade II meningiomas. Among patients with transformed Grade III meningiomas, 2 patients did not receive radiotherapy because they were considered palliative at the time of malignant transformation, 2 because they had a low performance status and were treated by fractioned radiosurgery and 2 because patients were lost to follow-up between surgeries. Fourteen patients had radiosurgery: ten patients had one radiosurgical procedure and 4 patients had 2 to 5 radiosurgical procedures. Radiosurgery was performed in addition to radiotherapy in ten patients. Chemotherapy was used for 5 patients (17%) without any radiological response. The different chemotherapy regimens were: 1) Bevacizumab then Vincristine/Ifosfamide/Cisplatin chemotherapy, 2) Sandostatin then Bevacizumab, 3) Bevacizumab, 4) Hydroxyurea with Bevacizumab and 5) Hydroxyurea. Mean follow-up lasted 91 months (range: 31-211 months). At the end of follow-up, 9 (31%) patients were dead, 9 (31) patients had a Karnofsky Performance Scale (KPS) of less than 50% and 11 (38%) had a KPS of more than 50%. Median progression free survival (PFS) was 11 months (mean: 17 - range: 1-105 months). PFS was shorter with each subsequent relapse. Principal characteristics of each group are summarized in Table 1. Median PFS were 16 months for patients with de novo Grade II meningiomas. In patients with Grade III meningiomas, the de novo subgroup had a median PFS of 4 months compared with 7 months in patients with transformation.

Pathological grading. The initial pathological diagnosis was Grade I in 2 patients, Grade II in 22 patients and Grade III in 5 patients. The two patients with initial Grade I meningioma progressed to Grade III after 1.1 and 12.2 years respectively. Among the patients initially diagnosed with Grade II meningioma, 10 progressed to Grade III (transformed meningioma) after a mean follow-up of 6.1 years (range: 1.2 – 14.7 years).

Radiological characteristics at diagnosis. All patients harbored non-skull base meningiomas
(9 convexity; 11 parasagittal; 3 falcorial; 4 tentorial; 2 pterional). Volumetric data was available for 11 patients at diagnosis. The mean tumor volume at diagnosis was 39.5 cm$^3$ (median: 35.6 cm$^3$).

Patterns of relapse. We describe three radiological patterns of relapse in our cohort: «classical», where a new tumor nodule grows back from the original site of dural insertion, «local multi-nodular», where multiple tumor nodules grow near the site of dural insertion or on the borders of the craniotomy and «multi-nodular metastatic», where multiple tumor nodules grow at several distant sites of dural insertion (Figure 1, A-D). Among the 29 patients analyzed, 9 (31%) had a «classical» relapse pattern, and 20 (69%) had a multi-nodular relapse including 6 (21%) with a «local multi-nodular» relapse and 14 (48%) with a «multi-nodular metastatic» relapse. In the latter group, there were two identified cases of metastatic dissemination along cerebrospinal fluid circulation pathways resulting in diffuse pachymeningeal thickening in one case, and multiple bi-hemispheric nodules in the other (Figure 1-D and 2-2). During progression, there was a mean number of 3.1 nodules per tumor.

We then looked at the precise sites of relapse. Most relapses were intracranial and inserted on the dura. No intraparenchymal relapses were identified. Subcutaneous relapses were operated upon in two cases. In the subgroup of 11 parasagittal meningiomas, the intrasinusal remnant was the site of recurrence in 7 cases (5 in the «classical» group and 2 in the «local multi-nodular» group). Interestingly, in the 4 cases of parasagittal meningiomas with «multi-nodular metastatic» pattern of relapse, the intrasinusal remnant had the lowest growth rate and was never the most aggressive tumor nodule. Finally, two cases of visceral metastases were encountered in our cohort.

We did not find any correlations between pathological grading and radiological patterns of relapses. Especially, in the group of tumors with multi-nodular metastatic relapses, we
confirmed that the onset of multiple nodules and malignant transformation did not occur simultaneously. In 8 cases, the tumor retained its initial pathological grade (4 WHO Grade II and 4 WHO Grade III) while presenting with a multi-nodular relapse. In 6 cases of tumors with malignant transformation, the transition to WHO Grade III and multi-nodular seeding occurred at the same time in only 3 cases.

**Kinetics of tumor growth.** Volumetric analysis of tumor growth concerned 95 tumor nodules in 50 relapses. The median growth rate of tumor nodules was 11.3 cm$^3$/year (mean: 45.5 cm$^3$/year - range : -1.2 - 1317 cm$^3$/year- 95% confidence interval: 16-75 cm$^3$/year) (Figure 1-E). In the « classical » group, data was available for two relapses in two patients. The growth rate was quite similar between the two relapses: 10.1 vs. 14.6 cm$^3$/year in the first case and 460,6 vs. 371 cm$^3$/year in the second case. In the « local multi-nodular » and « multi-nodular metastatic » groups, there was no correlation between the growth rates of the multiple tumor nodules of a single relapse, resulting in various patterns of tumor growth. Mean time to tumor progression (TTP) was 6.5 months (median: 3.5 months).

In multi-nodular relapses, we observed frequently an indolent growth of several tumor nodules while one to two nodules demonstrated the most aggressive clinical and radiological behavior (Figure 2). Assessing the global tumor burden to evaluate tumor growth and response would lead to an underestimation of the growth rate, especially in patients with multi-nodular relapses. We therefore decided to select target tumors corresponding to the growing nodules requiring complementary treatment. In 12 of 14 « multi-nodular metastatic relapses », the target tumor was a metastatic nodule and did not grew from the initial site of dural insertion. We selected 57 target tumors in 50 relapses among three radiological subgroups. The mean volume of target tumors at the time of treatment was 30,0 cm$^3$ (median : 21.8 cm$^3$) and their mean growth rate was 47.0 cm$^3$/year (median: 19.6 cm$^3$/year- 95%
confidence interval: 26.3 – 67.7 cm³/year). When considering only target tumors, mean TTP was 4.5 months (median: 2.3 months). Among radiological subgroups, mean TTP was lower in multi-nodular metastatic relapses (3.3 months) compared to classical relapses (5.5 months) (p=0.3).

In this series, kinetics of tumor growth shed light on the different patterns of treatment failure. Distant multi-nodular relapses occurring after radiotherapy are often too diffuse to be amenable to radiosurgery or gross-total resection, resulting in repeated incomplete surgeries (Figure 3). In the case of well-circumscribed tumor relapses, CSF dissemination may cause distant relapses despite local tumor control with radiotherapy (Figure 4).

**Discussion**

This retrospective study on surgery- and radiation-refractory meningiomas sheds new light on tumor growth patterns and tumor growth rates. Numerous chemotherapies have failed to demonstrate their efficacy [7-9], with the exception of a recent prospective study that has delivered promising results on the effects of sunitinib malate [10]. One explanation is that current criteria could underestimate responses of some nodules needing further investigations. Our data should help in the future establishment of precise response criteria in upcoming clinical trials. Macdonald criteria [16], often used to measure these tumors may not be accurate in this population, as pointed out in a recent meta-analysis [13]. It should be reminded that this study concerns a highly selected patient population and may therefore suffer from selection bias. But to our knowledge, this study also offers for the first time a precise volumetric evaluation of tumor growth in this population. In practice, linear measurements of coronal and axial sections are often inaccurate and have considerable inter- and intraobserver variations[17-19]. The use of semi-automated algorithms to determine tumor volume has already been performed in discrete tumors of the nervous system[20] and other
cancers[21] and has been found to be a reliable method to monitor tumor growth in patients, interobserver-variability being reduced to about half to one-third compared to standard manual measurements.

Here we illustrate the high variability of tumor growth rates, underlining the necessity of performing measurements to evaluate the tumor growth rate before starting a treatment in future clinical trials. We demonstrate the high frequency of multi-nodular relapses with different growth rates for each nodule (Figure 2) and therefore advocate for thorough evaluation of tumor growth, not considering the whole tumor burden but focusing on target tumors. This is all the more true considering that growing nodules at relapse are often found at a distant metastatic site. We may postulate that multi-nodular relapses may be caused by different genetic events in the initial tumor clone, leading to different tumorigenesis pathways and different rates of tumor growth. Targeted therapies should therefore focus on targeted lesions. This study also illustrates the patterns of treatment failure that may occur despite excellent tumor control on the initial site of dural insertion as illustrated in Figures 3 and 4. The frequency of distant relapses underlines the limits of local or loco-regional treatments such as surgery, radiosurgery and radiotherapy and should lead to an additional effort to find an efficient chemotherapy against those tumors. The different growth rates of each nodule may also reflect different tumorigenesis mechanisms with different sensitivities to chemotherapy. The efficacy of future treatments should therefore not be evaluated on the global tumor burden, at the risk of hiding potential antitumor effects on specific tumor nodules. These results emphasize the fact that multi-relapsing meningiomas represent a loco-regional disease of the meninge rather than an unique tumor and also explain a limited efficacy of radiosurgery with a frequent lack of coverage of the dural insertion volume, leading to multi-nodular local relapses.

The choice of an endpoint in clinical trials is another challenge in this population of
meningiomas that have failed surgery and radiotherapy. PFS-6 was the most consistently recorded endpoint in a recent literature review [13]. The PFS found in our study with \textit{de novo} and transformed Grade III meningiomas are consistent with this result. But the longer PFS found in Grade II meningiomas reminds us of the clinical heterogeneity of those tumors. The inclusion of Grade II meningiomas in future clinical trials should be limited to cases with histological progression and/or PFS of less than 6 months. The variation between PFS among different relapses from the same patient and different histological subgroups may also question the use of this criteria as an endpoint for future trials. The median TTP may appear as a more reliable endpoint as it considers only growth kinetics of the concerned relapse and nodule. A mean TTP of 3.7 months favors a regular follow-up of patients with multi-recurrent meningiomas, with a regular 3 month-interval between MRI-scans, instead of waiting for clinical deterioration.

This study also demonstrates the high heterogeneity of multi-recurrent meningiomas. On the histological level, our study adds new information on \textit{de novo} and transformed Grade III meningiomas. In previous reports [22,12], progressing tumors represented 54\% to 70\% of Grade III meningiomas. Here the high frequency (72\%) of progressing tumors among Grade III meningiomas might also be explained by a selection bias. As we selected multi-recurrent tumors, \textit{de novo} Grade III meningiomas leading to a fatal issue before the second operated relapse might have been excluded. In contrast to a previous study [12], we did not find a more aggressive clinical behavior in transformed compared to \textit{de novo} Grade III tumors. In regard of the small number of patients in both studies, we believe future clinical studies should be directed at answering this question. On the radiological level, our work confirmed that multi-recurrent meningiomas were mostly non-skull base tumors as already pointed out in several previous studies on the relationships between meningioma location and histological aggressiveness [23,24]. At relapse, we describe three different patterns of tumor growth. The
group of « multi-nodular metastatic » tumors represents almost 50% of tumor relapses and
demonstrates specific growth patterns: distant tumor nodules present increased growth rates
compared to nodules located at the initial dural insertion site and true CSF dissemination may
be encountered. CSF dissemination occurs in about 4% of meningiomas and preferentially in
highly-pretreated patients[25]. Contrary to the patients reported by Chamberlain et al., we did
not find any lepto-meningeal dissemination to the spinal cord in our cases. Extraneural
metastases were found in only one case. These patterns might correspond to a specific
underlying molecular mechanism that should be specifically addressed in future molecular
studies. In previous works, invasive properties of meningioma cells have been linked to
different migratory behaviors involving extracellular matrix modeling by tumor cells using
matrix metalloproteinases[26,27] and aquaporines[28].
In summary, surgery- and radiation-refractory meningiomas are predominantly progressing
tumors with malignant transformation and are characterized by frequent multi-nodular
metastatic relapses, representing a loco-regional disease amenable to systemic therapies.

Acknowledgments
The authors would like to thank Franck Maizeroi-Eugène for his kind gift of the Segmentix®
plugin.

Bibliography

C, Barnholtz-Sloan JS CBTRUS statistical report: Primary brain and central nervous system


Figure 1. Patterns of relapse in surgery- and radiation-refractory meningiomas. A. «Classical» relapse at the initial site of dural insertion. B. «Multi-nodular» local relapse near the initial site of dural insertion. C. «Multi-nodular metastatic» relapses at sites of dural insertion beyond the margins of the cranial flap. D. «Multi-nodular metastatic» relapse with diffuse pachymeningeal thickening in both hemispheres. E. Growth rates of tumor nodules in surgery- and radiation-refractory meningiomas (mm3/year). For seven nodules (in grey), the growth rates are over 100 cm³/year and indicated on the graph.
Figure 2. Differential growth of multiple tumor nodules originating from a single meningioma. This figure illustrates the differential growth of three distinct tumor nodules (blue and purple tumor and curves) originating from a single falcine meningioma (red tumor and curve).
Figure 3. Patterns of treatment failure in surgery- and radiation refractory meningiomas: distant CSF dissemination. This figure illustrates the case of a parasagittal Grade I meningioma (red curve and tumor) with initial metastatic relapse near the insertion site of a ventricular catheter (blue curve and tumor) with malignant transformation requiring protontherapy. Despite a local control of the irradiated nodules (red and blue tumors) this treatment failed to control tumor progression with the occurrence of a remote relapse (purple curve and tumor) at the clivus.
Figure 4. Patterns of treatment failure in surgery- and radiation refractory meningiomas: absence of local control. This case of a pterional Grade II meningioma illustrates the difficulty of local tumor control with repeated surgery. After the first surgery, the patient underwent radiotherapy and local control was achieved for the initial tumor bed (red tumor and curve). Two years after, the patient had an emergency craniotomy for a relapse with intratumoral hemorrhage revealing a transformed Grade III meningioma. Only 9 months after the second relapse, the patient had two fast growing distant relapses (blue and purple tumors and curves) not amenable to radiosurgery. These two relapses could not be controlled despite two extensive surgeries.
Table 1: Characteristics of the three subgroups

<table>
<thead>
<tr>
<th></th>
<th>Grade II Meningioma</th>
<th>De novo Grade III Meningioma</th>
<th>Transformed Grade III Meningioma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>11</td>
<td>5</td>
<td>13</td>
</tr>
<tr>
<td>Age of discovery (year)</td>
<td>52 (range, 40-68)</td>
<td>66 (range, 52-80)</td>
<td>53 (range, 31-76)</td>
</tr>
<tr>
<td>Sex:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>6</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Female</td>
<td>5</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>Relapses</td>
<td>2.4 (range, 2-6)</td>
<td>3 (range, 2-4)</td>
<td>3.3 (range, 2-7)</td>
</tr>
<tr>
<td>Surgery</td>
<td>2.9 (range, 2-5)</td>
<td>2.4 (range, 1-3)</td>
<td>4.2 (range, 2-7)</td>
</tr>
<tr>
<td>Radiosurgery</td>
<td>3</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Conformational radiotherapy</td>
<td>2</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Chemotherapy (patient – drug)</td>
<td>1 (Bevacizumab then VIP)</td>
<td>2 (1&lt;sup&gt;st&lt;/sup&gt;: Sandostatin then Bevacizumab – 2&lt;sup&gt;nd&lt;/sup&gt;: Bevacizumab)</td>
<td>2 (1&lt;sup&gt;st&lt;/sup&gt;: Hydroxyurea with Bevacizumab - 2&lt;sup&gt;nd&lt;/sup&gt;: Hydroxyurea)</td>
</tr>
<tr>
<td>Mean PFS (months) :</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1&lt;sup&gt;st&lt;/sup&gt; relapse - 2&lt;sup&gt;nd&lt;/sup&gt; relapse</td>
<td>33</td>
<td>13</td>
<td>33</td>
</tr>
<tr>
<td>2&lt;sup&gt;nd&lt;/sup&gt; relapse - 3&lt;sup&gt;rd&lt;/sup&gt; relapse</td>
<td>18</td>
<td>5</td>
<td>33</td>
</tr>
<tr>
<td>3&lt;sup&gt;rd&lt;/sup&gt; relapse - 4&lt;sup&gt;th&lt;/sup&gt; relapse</td>
<td>20</td>
<td>4</td>
<td>17</td>
</tr>
<tr>
<td>4&lt;sup&gt;th&lt;/sup&gt; relapse - 5&lt;sup&gt;th&lt;/sup&gt; relapse</td>
<td>10</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>Overall survival</td>
<td>99 (range, 49-211)</td>
<td>51 (range, 17-74)</td>
<td>108 (range, 31-201)</td>
</tr>
</tbody>
</table>